Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398086 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT00398086 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 67 participants.
The verdict
NCT00398086, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Albumin-bound paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2006-11-01 |
| Est. Completion | 2010-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00398086
The ClinicalTrials.gov registry entry for NCT00398086 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00398086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00398086 about?
NCT00398086 is a clinical study titled "Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer". To determine the maximum tolerated dose and dose-limiting toxicity of Gemcitabine plus Albumin-bound paclitaxel (ABI-007) in patients with advanced metastatic pancreatic cancer.
What is the current status of trial NCT00398086?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2006-11-01. Estimated completion is 2010-12-01.
What interventions are being tested in trial NCT00398086?
The interventions under investigation include: Gemcitabine (DRUG), Albumin-bound paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00398086?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.